Clinical Trial

Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall survival (OS).Secondary Objectives: Compare objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), duration of response (DoR), time to response (TTR), two-year OS rate, biomarker analysis, and quality of life (QoL).Safety: Assess and compare adverse event incidence and severity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-19; most recent amendment 2026-04-19.
Status change: Active, Not Recruiting → Recruiting 2026-04-19
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-05-13
Trial Details
NCT Number NCT06889688
Lead Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions Breast Cancer Stage IV, Triple -Negative Breast Cancer
Enrollment 246 participants
Start Date 2025-02-21
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-23